Takeda Sells Eye Drug to Novartis -- WSJ
09 Mai 2019 - 09:02AM
Dow Jones News
By Maria Armental
This article is being republished as part of our daily
reproduction of WSJ.com articles that also appeared in the U.S.
print edition of The Wall Street Journal (May 9, 2019).
Takeda Pharmaceutical Co., looking to pay down debt following
its megadeal for Shire PLC and narrow its focus, is selling eye
drug Xiidra to Novartis AG and TachoSil surgical patches and
sealants to Johnson & Johnson's Ethicon.
The deals, expected to close in the second half of the year,
would bring Takeda $3.8 billion in cash up front and up to $1.9
billion in additional payments from Novartis subject to certain
milestones being met, the companies said Wednesday.
Japan's Takeda has said it would sell about $10 billion worth of
assets to pay down debt.
Xiidra, which Takeda acquired as part of its January purchase of
drugmaker Shire, generated about $400 million in revenue last year
and is seen as a potential blockbuster drug. It competes with
Allergan PLC's No. 2 selling drug Restasis, which generated nearly
$1.3 billion in sales in 2018, much of which came from the U.S.
The eye-drop solution for dry-eye disease is approved for sale
in the U.S., Canada and Australia and under regulatory review in
additional markets.
As part of the agreement, about 400 workers associated with
Xiidra in the U.S. and Canada would join Novartis, the company
said.
Bloomberg reported earlier Wednesday that Novartis was
considering a bid for Xiidra.
As part of the deal with J&J, about 90 workers would join
Ethicon. But Takeda would continue to own a manufacturing site in
Linz, Austria, and make the TachoSil products for Ethicon under a
long-term agreement, Takeda said.
TachoSil generated about $155 million in sales in the year ended
March 31, 2018, Takeda said.
Takeda is scheduled to report financial results for the most
recent year next week.
Moody's Investors Service and S&P Global Ratings have cut
Takeda's credit ratings, citing a heavy debt load following the
company's Shire deal. Both firms said the deal drove a ratio of
debt to earnings well above that of pharmaceutical peers.
The company said Wednesday it is seeking to lower its
debt-to-earnings ratio in the medium term.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
May 09, 2019 02:47 ET (06:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024